News

Panthera adapts for COVID-19 virus - Letter from Stuart Young, CEO

As we all continue to adapt to the COVID-19 pandemic, we at Panthera are closely monitoring this rapidly evolving situation as well remaining vigilant to support clients and the NHS in any way we can.

Panthera sites will remain open for business with significant additional precautions to prevent transmission of the COVID-19 virus.

The safety of our staff, patients and staff from sponsors visiting our sites for essential activities, is our number one priority while we work with sponsors and CRO counterparts to assess each trial to see if it can carry on in a way that is safe both for clinicians and participants.

As we continue to grow as a business, we have created fantastic environments to run clinical studies but we are also looking for ways to use our capacity to support the heroic work being done by our friends and colleagues in front-line NHS services.

We are also encouraging sponsors running studies in NHS sites to contact us urgently if you are looking for safe, isolated clinical trial locations with dedicated trained research teams on standby.

Our World class team is ready to help tackle COVID-19!

Please don’t hesitate to contact me if you would like to discuss how we can help.

Regards,

Stuart Young, CEO

Independent site management organisation Panthera expands vaccine trial capacity

Panthera is now undertaking Phase II, III and IV vaccine trials on behalf of its pharma and CRO clients across its growing network of sites in the UK.

Panthera, which was founded by Dr Ian Smith, the founder of Synexus and Prof John Lyon, previously a Global Vice President at Covance, will continue to undertake trials for conditions treated in primary care including cardiovascular disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine.

CEO Stuart Young commented “We have been approached by several sponsors to run vaccine studies. Our very experienced team has a great deal of expertise in this area and with our increasing number of sites across the UK, we are well positioned to deliver both patients and healthy volunteers, who are at lower risk for COVID-19, for these trials.”

Panthera, which only launched in October last year, is continuing its planned expansion with an increase in its network of sites across the UK and discussions with partners on international expansion, and specialized services in neurology, oncology and NASH are in development.

Covid-19

The safety of clinical trial patients and staff is paramount and Panthera is working with its pharma and CRO clients to assess each trial to see if it needs to be suspended, delayed or if it can be continued in a way that is safe both for the clinicians and participants. Panthera is working with sponsors who need to press ahead with trials, particularly those trials involving patients in high-risk categories. Panthera already has remote patient visit protocols in place including using phone or video links. These links are also being used for monitoring and site inspections.

Because some of Panthera’s sites are stand-alone, Panthera is able to help on existing studies where enrolled patients can be moved – protocol permitting – from hospitals and GP practices which may be unsafe and challenging from a resource perspective, in the current environment.

With new sites coming on line Panthera can be very nimble and has the ability to adapt to the sponsor’s needs.

 

Independent SMO Panthera Biopartners continues to expand its network of clinical trial sites

  • Panthera’s second clinical trial site in the UK, in North Manchester is open for business.
  • As a standalone site ideal for existing or new trials with much lower contamination risk during COVID-19

Panthera is on track to have a network of sites open across the UK by the end of the year and is continuing to invest in growth despite the increasingly challenging environment created by the COVID-19 pandemic.

CEO Stuart Young commented “We are adapting our plans to support the efforts of those tackling the COVID-19 pandemic while also pursuing the long-term goal to provide exemplar, independently run clinical trial sites across the UK and beyond. We are already able to provide top class clinical facilities in Preston and Manchester and are looking to build that network much further putting the patient at the heart of what we do.”

He continues, “This pandemic has highlighted the need for more clinical research across the globe. We are keen to play our part to help in the short term in any way we can. However, in the longer term, we are focussed on providing our customers in pharma and CROs with a better solution.”

Panthera, as an independent SMO, with one of the most experienced teams in the industry, has attracted the attention of all the major CROs and pharma companies, and is offering sites for their traditional specialities in vaccines, general medicine and primary care conditions.

Panthera is also in advanced discussions in providing specialist secondary care sites for trials in neurology and oncology.

Founded by Dr Ian Smith, founder of Synexus, and Prof. John Lyon previously a senior global executive in Covance, the team also includes CCO Jane Restorick who was previously the global COO at Synexus and CEO Stuart Young, former MD Synexus UK.

Stephen Doherty leads the team of experienced GCP trained staff at the new North Manchester site, which will focus on trials in conditions treated in primary care including cardiac disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine.

The site facilities will include seven consulting rooms, a fully equipped laboratory, with state of the art research facilities and ample parking for patients.

Independent site management organisation Panthera prepares for COVID-19

The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to asses each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants” commented Stuart Young CEO of Panthera the independent SMO.”

Stuart continued, “the major regulatory bodies across the world – FDA, MHRA and EMA – have given clear guidelines, with safety being the number one consideration. I have outlined below how we are proceeding.”

  • Panthera is working with sponsors who need to press ahead with trials which can be done safely.
  • Trials involving patients who are in the high-risk categories will be managed with extreme caution and Panthera will work with sponsors on appropriate measures and recruitment pauses as needed.
  • Panthera already has remote patient visit protocols in place including using phone or video links. These links could also be used for monitoring and site
    inspections.
  • During this pandemic any visit by a patient has been mapped out so that there is a greatly reduced risk of contamination. Patients are asked to remain in their vehicles until the healthcare professional is ready for them. A thorough hygiene regime is also in place.
  • With new sites coming on line, Panthera can be very nimble and has the ability to adapt to the sponsor’s needs.
  • Because some of Panthera’s sites are isolated Panthera is able to help on existing studies where enrolled patients can be moved – protocol permitting – from hospitals and GP practices which may well be unsafe in this current environment.

Panthera which has sites in Manchester and Preston has only just opened a new site in North Manchester. The North Manchester site which is a standalone building with its own car park has seven consulting rooms and all the technical facilities required to run a professional clinical trial site. The GCP trained staff will manage trials on conditions served by primary care.

The Panthera Preston site will be expanding next year when it moves into a
purpose-built super-practice which is presently under construction.

Panthera plans to open a network of sites across the UK. It is also in advanced discussions in providing specialist secondary care sites for trials in Neurology and Oncology.

Panthera Biopartners strengthens team with the appointment of Joanna Cox as Operations Director

Independent site management organisation (SMO) Panthera Biopartners has appointed Joanna Cox as its Operations Director. Joanna joins the Panthera team from Lancashire Care NHS Foundation Trust, where she was the Senior Research Nurse responsible for the day to day management of the clinical research team across a wide portfolio of trials. Previously Joanna has also worked as Clinical Trial Manager at UCLan, and Senior Research Nurse at Salford Royal Foundation as well as in a senior position at Synexus.

Panthera’s CEO, Stuart Young, commented, “With her years of experience in running clinical trials, both within the NHS and commercially, Joanna is an outstanding addition to the very experienced Panthera team. Her clinical and patient management expertise is a huge asset for us going forwards, and I am hugely excited to be working with her.”

Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac
disease, allergies, migraine, osteoarthritis, diabetes. etc. It will also expand into other key indications including neurology and oncology later this year.

The company which opened its first clinical trial site in Preston, Lancashire, UK in November 2019 is in advanced discussions to open two more sites one in South Manchester and one in North Manchester shortly. Further sites are planned across the UK and then overseas.

The Panthera site model is to locate their clinics either in mega GP practices – more than 100,000 patients –or at major hospitals ensuring that there is an easily accessible patient pool and connected services.

Panthera’s clinical trial site in Preston, UK, open for business

  • First of more than four UK sites planned for 2020
  • In negotiation on international expansion
  • Specialist Oncology and Neuroscience sites – planning underway

Panthera, the newly launched independent clinical trial site management organisation (SMO), has opened its first site in Preston in the UK with a second site in North Manchester to open in March. This is in line with the company’s aim to have at least four sites in the UK by the end of 2020.

Stuart Young, CEO of Panthera, commented “We are really making progress. We can now offer our CRO and pharma clients the ability to recruit thousands of patients in trials which involve the many conditions treated in primary care.”

All of the Panthera sites are or will be strategically located to maximise partnerships
within NHS mega primary care sites or at major hospital trusts. This ensures that each site has access to substantial patient numbers, key clinical skills and works closely with the health service.

The Panthera Preston site will be expanding next year when it moves into a purpose-built super-practice which is presently under construction under the leadership of site manager, Gillian Woods.

Panthera is in advanced discussions on a South Manchester site, which they are planning to open in May, and are in negotiation with several other sites including
Glasgow.

Specialist models to deliver oncology, neurology and NASH patients are being developed for later in the year with discussions on sites in Europe also being pursued.

“What is really encouraging is the interest from both pharma and CROs who continue to look for high quality, independent sites to deliver large numbers.” continued Stuart “We have been inundated with enquiries. With our dedicated team, we are able to quickly respond to requests for feasibilities and can contract quickly to avoid unnecessary delays. This enables us to begin recruiting within weeks rather than months.”

Led by founders Chairman Professor John Lyon, previously a senior global executive in Covance, and Dr Ian Smith, Chief Medical Officer and founder of Synexus, Panthera has assembled one of the most experienced teams in the SMO industry. Other executives include CEO Stuart Young, formerly UK country manager of Synexus and Jane Restorick, Chief Commercial Officer of Panthera formerly Chief Operating Officer of Synexus.

Independent Panthera Biopartners appoints Stuart Young as CEO as the company further strengthens its team.

Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Stuart Young as chief executive. Stuart who was previously UK Country Manager of Synexus will lead the organisation’s expansion across the UK and into Europe. Panthera which opened its first clinical trial site in Preston, in the NW of England, late last year now has a full management team in place.

Stuart previously managed the UK division of Synexus overseeing nine dedicated
research sites. Stuart is particularly focussed on the use of technology to reduce costs in clinical trials, provide a first rate patient experience and ensure that Panthera is at the cutting edge of clinical research. Stuart, who holds a degree in Mechanical Engineering from University of Strathclyde in Glasgow has had extensive experience in data management and the introduction of new technologies into organisations.

Stuart joins Chairman, Chief Financial Officer and co-founder Professor John Lyon, who was previously a global executive in CRO Covance; Medical Director and co-founder Dr Ian Smith, who previously founded Synexus and Jane Restorick, Chief
Commercial Officer, who was most recently Chief Operating Officer and Chief Patient Officer at Synexus.

Stuart commented  ”I am delighted to join such an experienced team. Our collective expertise in running clinical trials across the globe is second to none. While we are just starting our journey we are already on target to open more sites in the UK; we are in discussions on expanding across Europe; and most importantly as an independent organisation with a world class team we have been received very warmly by both CROs and pharma.”

Chairman John Lyon, “We are really pleased to welcome Stuart as CEO of Panthera. Not only does he know the clinical trial business inside out he has the understanding and technical knowledge to ensure that Panthera is a world leader in the introduction  of technology into all aspects of recruiting patients, running and reporting on clinical trials.”

Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, diabetes. etc. It will also expand into other key indications including neurology and oncology.

The company opened its first clinical trial site in Preston, Lancashire, UK in November 2019. The clinical trial site, which is the first of a number of planned across the UK and overseas, is already involved in implementing trials on behalf of its clients from CROs and pharma companies.

Panthera strengthens management team with appointment of experienced clinical research executive, Jane Restorick

Panthera Biopartners, an independent SMO (Site Management Organisation) which recently launched its first UK clinical research site, has strengthened its management team with the appointment of Jane Restorick as Chief Commercial Officer. Jane brings with her more than thirty years’ experience in clinical research, most recently as Chief Operating Officer and Chief Patient Officer at Synexus Clinical Research.

During her seventeen years at Synexus, Jane worked across a wide spectrum of clinical research operations, including feasibility, programme management, patient engagement, and global site operations. Since leaving Synexus in 2018, Jane has been a consultant to the Pharmaceutical industry with her own company, Arion Consulting Services.

Dr Ian Smith, co-founder of Panthera Biopartners and founder of Synexus, commented, “I am thrilled that Jane has joined the Panthera team, and to be working with her again. Jane’s experience in clinical research operations is going to be hugely valuable for Panthera as we continue to grow and expand.”

Panthera Biopartners was founded by Dr Ian Smith, founder of Synexus, and Professor John Lyon, previously a global executive at Covance. Panthera opened its first clinical trials site in Preston, Lancashire, UK in November 2019, , and will be
initiating its first trials on behalf of  CROs and pharma companies, in the coming months.  Preston is the first of a number of planned sites in the UK and overseas

Panthera will initially recruit patients and run clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis, diabetes etc. In 2020 the company is looking to expand into trials for NASH (fatty liver disease) in primary care, and Oncology and Neurology in secondary care.

Independent SMO Panthera Biopartners launches with its first clinical trial site in the UK

  • First clinical trial site in Preston, North England, open for business.
  • Three trials already in the pipeline.
  • At least three further sites to open in the UK in 2020.
  • Dr Ian Smith founder of Synexus – the world’s largest SMO – is one of the founders of Panthera.
  • In discussions on international expansion.

Independent SMO (Site Management Organisation) Panthera Biopartners has opened its first clinical trials site in Preston, Lancashire, UK. The clinical trial site, which is the first of a number of planned sites in the UK and overseas, is already involved in implementing trials on behalf of its clients from CROs and pharma companies.

Panthera Biopartners was founded by Dr Ian Smith, who previously founded Synexus and Professor John Lyon, who was previously a global executive in CRO Covance and a serial entrepreneur. The company is presently raising it’s “A” round of finance which will be concluded shortly.

Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis, diabetes etc.

In the New Year the company is looking at NASH in primary care and Oncology and Neurology for secondary care.

The Panthera team has very wide experience in providing feasibility, recruitment, running of clinical trials and retention across a broad range of therapy areas. All the healthcare staff at the Preston Panthera site are GCP trained with considerable experience in the recruiting of patients and running of clinical trials.

Dr Ian Smith, Founder and Medical Director of Panthera commented “It has been so encouraging talking to CROs and major pharma companies. They have really welcomed the entry of Panthera Biopartners as an independent SMO which incorporates new technology into the running of clinical trials and the recruitment of patients.

We plan to have a number of sites up and running by the first quarter of 2020 with an ongoing expansion program across the UK and overseas.”

Panthera will be shortly announcing a CEO and other senior appointments.